MOUNTAIN VIEW, Calif., November 14, 2024--(BUSINESS WIRE)--Olfactive Biosolutions, the leader in harnessing food molecules ...

For patients with opioid use disorder (OUD) and alcohol use disorder (AUD), prescriptions of glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon-like peptide-1 receptor agonists (GLP-1 ...

Eli Lilly), a dual GLP-1/glucose-dependent insulinotropic peptide (GIP) agonist. That’s because of their high cost, the large ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

The GLP-1 medications liraglutide and semaglutide, as well as the dual GLP-1 and glucose-independent insulinotropic ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

The GLP-1 medications liraglutide and semaglutide, as well as the dual GLP-1 and glucose-independent insulinotropic polypeptide (GIP) tirzepatide, are approved by the U.S. Food & Drug Administration ...

while its dual GLP-1/GIP agonist tirzepatide was approved for diabetes in May and for obesity just last week. Outside China, the tirzepatide products are known as Mounjaro and Zepbound ...